Rapport CEO Abe Ceesay said the company is 'fully prepared' to launch its seizure drug independently, positioning the biotech to join the ranks of successful commercial-stage neuroscience companies. In a wide-ranging interview, Ceesay detailed the strategy behind building an investor syndicate to support the solo launch.
Ceesay emphasized that Rapport has assembled the necessary financial backing and operational capabilities to bring the drug to market without a larger pharmaceutical partner. The company's confidence stems from its specialized focus on central nervous system disorders and a tailored commercial infrastructure.
The move reflects a broader trend in biotech where smaller firms pursue independent commercialization in niche therapeutic areas, despite the high costs and risks associated with direct-to-market strategies. Rapport's approach aims to capture more value from its drug if successful.
Analysts note that going solo avoids sharing profits but increases financial exposure if sales disappoint. The company must now prove its commercial execution against established competitors in the epilepsy market.
Ceesay's comments come as Rapport advances toward a launch timeline that has not been publicly specified. Investors will be watching for sales data and payer uptake as key indicators of the strategy's viability.